For our 10th episode of the Free Radicals podcast,
@EricDai_BioE and I are excited to host
@KarlPfleger
After a decade as one of the first AI researchers at Google from 2002 to 2011, Karl dedicated himself to the cause of rejuvenation biotechnology.
He is a philanthropist, community builder, and prolific angel investor with over 35 investments into rejuvenation biotech startups. His website,
agingbiotech.info, provides valuable information to the entire field, and his talks and X posts are highly insightful and influential within longevity.
Karl has deeply researched and nuanced takes, and those really show in this conversation. We cover why epigenetic reprogramming wonât solve aging, Karlâs investment strategy, what distinguishes true rejuvenation technology, why better diagnostic technologies could be the key to personalized aging interventions, and much more.
Special thank you to
@NFX &
@omri_drory for lending us their beautiful podcasting studio!
0:00 Intro
1:56 Peter Attia and defining longevity
8:37 What is aging?
12:41 Wear and tear vs programmed obsolescence
16:12 Which molecular mechanism of aging do we have the most control over?
19:29 Does partial reprogramming solve the whole aging problem?
25:23 How to identify truly rejuvenating therapies
32:35 The role of AI and good screening technologies
37:03 Do we understand the mechanisms of aging well enough to intervene?
38:39 Will there be a longevity tipping point?
44:51 Karl's investment strategy for aging biotech
52:21 Senolytics
1:01:33 Misfolded protein clearance & mitochondrial transplantation
1:08:21 Sauna & parabiosis (not combined)
1:15:54 Stem cell therapies
1:22:02 Karl's research process & formal techniques for evaluating arguments
1:28:55 The successes of the geroscience paradigm
1:34:13 Diagnostic bottlenecks